Literature DB >> 12576828

Comparison of open surgery versus retroperitoneoscopic approach to chyluria.

Xu Zhang1, Zhang-Qun Ye, Zhong Chen, Zhi-Qiang Chen, Qing-Guo Zhu, Ma Xin, Long-Cheng Li.   

Abstract

PURPOSE: We compared the clinical effectiveness of renal pedicle lymphatic disconnection for chyluria performed by retroperitoneoscopy and by open surgery.
MATERIALS AND METHODS: Three male and 4 female patients 33 to 68 years old (mean age 49) with chyluria underwent retroperitoneoscopic renal pedicle lymphatic disconnection. Chyluria was on the left side in 5 cases and on the right side in 2. Open renal pedicle lymphatic disconnection was performed in 4 men and 2 women 33 to 61 years old (mean age 45.8). Chyluria was on the left and right sides in 3 cases each. Mean operative time, intraoperative blood loss, postoperative intestinal function recovery time, intraoperative and postoperative complications, postoperative hospital delay and operative outcome were compared in these 2 groups.
RESULTS: Compared with the open surgery group results in the retroperitoneoscopic group were superior in terms of operative time (42 to 90 minutes, mean +/- SD 65.0 +/- 18.8 versus 120 to 220, mean 156.7 +/- 38.8), intraoperative blood loss (20 to 50 ml., mean 29.3 +/- 10.2 versus 60 to 250, mean 171.7 +/- 76.5), postoperative intestinal function recovery time (24 to 48 hours, mean 36.0 +/- 6.9 versus 24 to 72, mean 54.0 +/- 21.1), intraoperative and postoperative complications, and postoperative hospital stay (3 to 6 days, mean 4.7 +/- 0.7 versus 7 to 9 days, mean 7.8 +/- 1.0). In the open surgery group primary anastomosis was performed in 1 case due to injury to a renal artery branch during the operation. Chyluria resolved the day after surgery in the 2 groups. No obvious complications developed postoperatively. The followup of 2 to 12 months (mean 6.7 +/- 4.0) showed no recurrence of chyluria.
CONCLUSIONS: Retroperitoneoscopic renal pedicle lymphatic disconnection completely ligates the lymphatic vessels with minimal invasion, less blood loss, rapid recovery and a good short-term outcome.

Entities:  

Mesh:

Year:  2003        PMID: 12576828     DOI: 10.1097/01.ju.0000045090.45767.56

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

1.  It is unnecessary to completely mobilize the kidney in retroperitoneoscopic renal pedicle lymphatic disconnection for intractable chyluria.

Authors:  Tao Zhang; Jinyou Wang; Dexin Yu; Jiaxing Ma; Haoqiang Shi; Liangkuan Bi; Dongdong Xie; Yi Wang; Jie Min
Journal:  Int Urol Nephrol       Date:  2016-06-30       Impact factor: 2.370

Review 2.  Robotic surgery for treatment of chyluria.

Authors:  Naman Barman; Michael Palese
Journal:  J Robot Surg       Date:  2016-02-09

3.  Modified technique of renal pedicle lymphatic disconnection for chyluria through the laparoscopic surgery.

Authors:  Liang Tang; De-Xin Yu; Wei-Hua Fang; Hao-Qiang Shi
Journal:  Int J Clin Exp Med       Date:  2014-09-15

4.  Is single dose povidone iodine sclerotherapy effective in chyluria?

Authors:  Anil Shrestha; Parash Mani Shrestha; Rakesh Verma
Journal:  Int Urol Nephrol       Date:  2014-01-14       Impact factor: 2.370

5.  Modified retroperitoneoscopic port sites for surgery of upper urinary tract.

Authors:  Dongliang Hu; Xinghuan Wang; Wanli Hu
Journal:  JSLS       Date:  2014 Jul-Sep       Impact factor: 2.172

6.  Single versus multiple instillation of povidone iodine and urographin in the treatment of chyluria: A prospective randomised study.

Authors:  Mohammed M Seleem; Ahmed M Eliwa; Ehab R Elsayed; Hamdy Desouky; Hazem El Galaly; Khalid Abdelwahab; Salem Khalil; Mahmoud El Adl
Journal:  Arab J Urol       Date:  2016-04-26

7.  Bilateral Synchronous Sporadic Renal Cell Carcinoma: Retroperitoneoscopic Strategies and Intermediate Outcomes of 60 Patients.

Authors:  Baojun Wang; Huijie Gong; Xu Zhang; Hongzhao Li; Xin Ma; Erlin Song; Jiangping Gao; Jun Dong
Journal:  PLoS One       Date:  2016-05-02       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.